Send to

Choose Destination
Cancer Res Treat. 2010 Sep;42(3):180-4. doi: 10.4143/crt.2010.42.3.180. Epub 2010 Sep 30.

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.

Author information

Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.


The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.


Renal cell carcinoma; Renal dialysis; Sunitinib

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center